BSH in Patients with Malignant Glioma: Distribution in Tissues, Comparison Between BSH Concentration and Histology

The treatment of malignant brain tumors, especially glioblastoma multiforme, presents great problems to the therapeutic disciplines. Despite technical advances in the surgical management and the perioperative treatment, a successful surgical approach is improbable, due to the diffuse and infiltrating growth of the tumor. From the standpoint of the radiotherapist the low tolerance of the normal brain tissue limits the delivery of tumor effective radiation dosages. Finally, chemotherapy has shown to be ineffective in bringing about lasting remission of malignant glioma (WHO III/IV) or even incontrol tumor growth. Even the current aggressive multimodality therapy did not result in an average survival time of longer than 12 months. One is still faced with an infaust and very depressing prognosis for the patient suffering from a glioblastoma multiforme.